SS-31 Research Guide: Mitochondria-Targeted Antioxidant Peptide — Mechanism & Studies

SS-31 (Szeto-Schiller peptide 31), also known as elamipretide or MTP-131, is a synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) developed by Hazel Szeto and Peter Schiller at Weill Cornell Medical College. SS-31 belongs to a class of aromatic-cationic peptides (ACPs) that selectively concentrate in the inner mitochondrial membrane (IMM) at concentrations several hundred-fold above cytoplasmic levels, targeting the primary site of reactive oxygen species (ROS) generation in cells. This selective mitochondrial accumulation, without requiring membrane potential, and its documented effects on cardiolipin, mitochondrial cristae structure, and electron transport chain efficiency make SS-31 one of the most extensively studied mitochondria-targeted antioxidant compounds in preclinical and early clinical research.

For research use only. Not intended for human or veterinary use.

Background: Mitochondrial Dysfunction and Oxidative Stress

Mitochondria are the primary cellular site of ATP production via oxidative phosphorylation (OXPHOS), but also the primary source of reactive oxygen species (ROS) under physiological and pathological conditions. Electrons leaking from complexes I and III of the electron transport chain react with molecular oxygen to form superoxide, which is converted to hydrogen peroxide and other ROS. While low-level ROS serves signaling functions, excessive ROS, particularly when antioxidant defenses are overwhelmed, causes mitochondrial DNA damage, lipid peroxidation, protein oxidation, and ultimately cell death.

Mitochondrial dysfunction characterized by elevated ROS, impaired electron transport, and disrupted cristae architecture is a shared pathological mechanism in ischemia-reperfusion injury, heart failure, neurodegenerative diseases, renal disease, and aging. Targeting antioxidant therapy directly to the inner mitochondrial membrane, the primary ROS source, has been a major research goal, and SS-31 is the most clinically advanced compound in this class.

Structure and Properties

• Sequence: D-Arg-Dmt-Lys-Phe-NH2 (Dmt = 2′,6′-dimethyltyrosine; C-terminal amide; alternating aromatic-cationic residues)
• Molecular weight: 639.8 Da
• IMM accumulation: Concentrates 1,000–5,000-fold in inner mitochondrial membrane relative to cytoplasm; accumulation is independent of mitochondrial membrane potential (unlike triphenylphosphonium-conjugated antioxidants)
• Primary target: Cardiolipin, a unique phospholipid found almost exclusively in the IMM
• ROS scavenging: Dmt residue provides direct superoxide and hydrogen peroxide scavenging via aromatic radical stabilization
• Half-life: Approximately 1–2 hours; subcutaneous administration produces more sustained plasma levels than IV in rodent studies

Mechanism of Action

Cardiolipin Interaction and Cristae Remodeling

The central molecular mechanism of SS-31 involves its high-affinity interaction with cardiolipin, a dimeric phospholipid that constitutes approximately 20% of IMM lipids and is essential for the structural and functional integrity of OXPHOS complexes. Cardiolipin anchors cytochrome c to the IMM surface and is required for the proper assembly and activity of respiratory chain supercomplexes. Under oxidative stress, cardiolipin is peroxidized by cytochrome c’s peroxidase activity, a process that releases cytochrome c into the cytoplasm and initiates the intrinsic apoptotic pathway.

Birk et al. (2013) demonstrated that SS-31 binds cardiolipin directly, inhibiting its peroxidation by cytochrome c peroxidase activity. This cardiolipin protection preserves IMM structure, maintains cytochrome c in its electron transfer role (rather than its peroxidase role), and prevents release of pro-apoptotic signals. Subsequent structural studies showed that SS-31-cardiolipin binding also promotes IMM cristae remodeling, restoring the tight cristae folds that optimize proton gradient utilization for ATP synthesis efficiency.

Electron Transport Chain Efficiency

Beyond direct ROS scavenging and cardiolipin protection, SS-31 has been shown to enhance electron transport chain coupling efficiency, the relationship between electron flux and ATP produced per oxygen consumed. Szeto et al. (2014) demonstrated that SS-31 increased state 3 respiration (ADP-stimulated), improved respiratory control ratios, and reduced proton leak in mitochondria isolated from aging and disease model animals. These effects are consistent with improved cristae architecture restoring the structural organization of OXPHOS supercomplexes rather than direct enzyme activation.

Membrane Potential-Independent Accumulation

A pharmacologically important property of SS-31 is its accumulation in the IMM independent of membrane potential. Earlier mitochondria-targeted compounds (such as MitoQ, a triphenylphosphonium-conjugated coenzyme Q analog) relied on the highly negative mitochondrial membrane potential (~−180 mV) for electrophoretic concentration in mitochondria. This means they cannot accumulate in depolarized mitochondria, precisely the dysfunctional mitochondria present in ischemic and diseased tissue where therapeutic benefit is most needed. SS-31’s membrane-potential-independent IMM accumulation through cardiolipin binding overcomes this limitation, making it effective in pathological mitochondria where other targeted antioxidants fail to concentrate.

Key Research Findings

Cardiac Ischemia-Reperfusion Injury

Ischemia-reperfusion (IR) injury, paradoxically worsened by restoration of blood flow due to ROS burst, is a primary target of SS-31 research. Zhao et al. (2004) demonstrated that SS-31 administration before reperfusion significantly reduced myocardial infarct size, preserved cardiac function, and reduced cardiomyocyte apoptosis in rodent IR models. Subsequent studies confirmed these findings across multiple species and surgical IR protocols, with SS-31 consistently reducing mitochondrial ROS burst at reperfusion and preserving cristae structure through the injury-reperfusion cycle.

Heart Failure and Aging Cardiac Models

Chronic heart failure is characterized by progressive mitochondrial dysfunction, impaired bioenergetics, and cardiomyocyte apoptosis. Dai et al. (2013) demonstrated that chronic SS-31 administration in a mouse pressure-overload heart failure model preserved mitochondrial cristae structure, maintained respiratory chain supercomplex assembly, and significantly improved cardiac function (ejection fraction, exercise tolerance) versus vehicle. These findings connected SS-31’s molecular cardiolipin-protective mechanism to functional cardiac outcomes and supported its advancement toward clinical heart failure trials.

Renal Research

The kidney, particularly the proximal tubule, has among the highest mitochondrial density of any tissue and is highly susceptible to oxidative mitochondrial injury. SS-31 has been studied in models of acute kidney injury (AKI), contrast nephropathy, and cisplatin-induced nephrotoxicity. Birk et al. (2013) and related studies documented significant renal protection with SS-31 in IR and nephrotoxin models, with reduced tubular apoptosis, preserved glomerular filtration, and maintained mitochondrial morphology in treated kidneys. These findings have driven SS-31’s advancement into clinical trials for renal protection.

Skeletal Muscle and Aging

Sarcopenia, age-related skeletal muscle loss, is associated with progressive mitochondrial dysfunction in muscle fibers. Siegel et al. (2013) demonstrated that SS-31 treatment in aged mice improved skeletal muscle mitochondrial function, reduced oxidative damage, and partially restored exercise capacity, findings consistent with mitochondrial rejuvenation in aged muscle. This has positioned SS-31 alongside MOTS-c as a research tool for dissecting mitochondrial aging in skeletal muscle biology.

Clinical Trials (Elamipretide)

SS-31 (as elamipretide/MTP-131) has advanced into multiple Phase I and Phase II clinical trials, primarily in heart failure and Barth syndrome (a rare mitochondrial cardiomyopathy caused by tafazzin mutations impairing cardiolipin remodeling). Phase II data in heart failure with reduced ejection fraction (HFrEF) demonstrated improvements in mitochondrial function biomarkers and exercise capacity, though the primary endpoint in the PROGRESS-HF trial was not met. Barth syndrome trials showed more promising results consistent with the direct cardiolipin mechanism, a genetically validated target. These clinical datasets provide human safety and pharmacokinetic data relevant to the broader SS-31 research program.

Reconstitution Protocol

SS-31 is supplied as a lyophilized powder requiring reconstitution with bacteriostatic water prior to research use.

• Inject bacteriostatic water slowly along the inner wall of the vial; do not direct the stream onto the lyophilized powder
• Gently swirl until fully dissolved; solution should be clear and colorless
• Common research concentration: 5 mg/mL
• Refrigerate reconstituted solution at 2–8°C; stable approximately 4 weeks; protect from light
• Do not freeze reconstituted solution; lyophilized powder may be stored at -20°C

References

• Szeto, H. H. (2008). Mitochondria-targeted cytoprotective peptides for ischemia-reperfusion injury. Antioxidants and Redox Signaling, 10(3), 601–619.
• Birk, A. V., Liu, S., Soong, Y., Mills, W., Singh, P., Warren, J. D., … & Szeto, H. H. (2013). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology, 24(8), 1250–1261.
• Zhao, K., Zhao, G. M., Wu, D., Soong, Y., Birk, A. V., Schiller, P. W., & Szeto, H. H. (2004). Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. Journal of Biological Chemistry, 279(33), 34682–34690.
• Dai, D. F., Hsieh, E. J., Chen, T., Menard, A., & Bhatt, D. L. (2013). Global proteomics and pathway analysis of pressure-overload-induced heart failure and its attenuation by mitochondrial-targeted peptides. Circulation: Heart Failure, 6(5), 1067–1076.
• Siegel, M. P., Bhatt, D. L., & Marcinek, D. J. (2013). Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell, 12(5), 763–771.

All content on this site is intended strictly for in vitro research and laboratory use. Products sold by Exceed Enhancement are not approved by the FDA and are not intended for human consumption, therapeutic use, or veterinary application.

Research-Grade SS-31 Available

Exceed Enhancement offers research-grade SS-31 for qualified research applications. View product specifications and ordering information →